This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutDosing & Product InformationDosing and Product InformationDosing and StorageOrdering and CodingEfficacy & SafetyEfficacy and
SafetyClinical Data in Support of BiosimilaritySafety Data in Support of BiosimilaritySavings & SupportSavings and SupportSupport and ResourcesMaterialsPfizer Commitment

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-RET-USA-0370
You are now leaving PfizerYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-RET-USA-0350
INDICATIONS ANEMIA DUE TO CHRONIC KIDNEY DISEASE RETACRIT® is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis, to decrease the need for red blood cell (RBC) transfusion. ANEMIA DUE TO ZIDOVUDINE IN PATIENTS WITH HIV INFECTION RETACRIT® is indicated for the treatment of anemia due to zidovudine administered at ≤4,200 mg/week in patients with Human Immunodeficiency Virus (HIV) infection with endogenous serum erythropoietin levels of ≤500 mUnits/mL.​​​​​​​ ANEMIA DUE TO CHEMOTHERAPY IN PATIENTS WITH CANCER RETACRIT® is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.REDUCTION OF ALLOGENEIC RED BLOOD CELL TRANSFUSIONS IN PATIENTS UNDERGOING ELECTIVE, NONCARDIAC, NONVASCULAR SURGERYRETACRIT® is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin >10 to ≤13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. RETACRIT® is not indicated for patients who are willing to donate autologous blood preoperatively. Limitations of Use RETACRIT® has not been shown to improve quality of life, fatigue, or patient well-being. RETACRIT® is not indicated for use:
  • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy
  • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure
  • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion
  • In patients scheduled for surgery who are willing to donate autologous blood
  • In patients undergoing cardiac or vascular surgery
  • As a substitute for RBC transfusions in patients who require immediate correction of anemia
Please see full Prescribing Information, including BOXED WARNINGS, Medication Guide, and Instructions for Use,for RETACRIT.